{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:21:11Z","timestamp":1773098471692,"version":"3.50.1"},"reference-count":8,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T00:00:00Z","timestamp":1448409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (<jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content>) remains a concern after organ transplantation. In 2005, the University of Kentucky (<jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>) Transplant Center implemented a novel dosing regimen of weekly dapsone as an alternative for patients with contraindications or intolerability to trimethoprim\u2010sulfamethoxazole (<jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content>), which remains the drug of choice. The purpose of this study was to compare the efficacy of weekly dapsone with <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> in preventing <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> post transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010center, cohort, retrospective review of kidney and liver transplant patients from January 2005 to December 2012 was conducted. Patients who were identified as dapsone cases were matched in a 1:1 ratio with <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> controls based on type of transplant, age, primary diagnosis, and gender. The primary endpoint assessed was the diagnosis of <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> at 6 and 12 months post transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 158 patients were included in the study. No documented cases of <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> occurred in either study group at 6 or 12 months (<jats:italic>P<\/jats:italic> = 1.0). In dapsone patients 35 (44%) cases of breakthrough infection occurred, compared to 24 (30%) in the <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> group (<jats:italic>P<\/jats:italic> = 0.07) within 12 months post transplant. In the dapsone group, 52 (65%) patients were hospitalized within 6 months post transplant compared to 36 (46%) patients in the <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> group (<jats:italic>P<\/jats:italic> = 0.01). Similar results were seen in patients hospitalized within 12 months post transplant; 49% of patients were switched from <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> to dapsone owing to renal dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No documented cases of <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> occurred in either study group. Future studies are warranted to show the efficacy of weekly dapsone dosing compared to other <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> prophylaxis regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12457","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T10:33:30Z","timestamp":1442313210000},"page":"816-821","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of once\u2010weekly dapsone dosing for <i><scp>P<\/scp>neumocystis jirovecii<\/i> pneumonia prophylaxis post transplantation"],"prefix":"10.1111","volume":"17","author":[{"given":"R.A.","family":"Evans","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services University of Kentucky Healthcare Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Clifford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services University of Kentucky Healthcare Lexington Kentucky USA"},{"name":"University of Kentucky College of Pharmacy Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Thomas Jefferson University Hospital Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Au","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Pharmacy Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Fugit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services University of Kentucky Healthcare Lexington Kentucky USA"},{"name":"University of Kentucky College of Pharmacy Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/320897","article-title":"Epidemiology of infections after solid organ transplantation","volume":"33","author":"Snydman DR","year":"2001","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12119"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-10-199505150-00004"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/320901"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/514626"},{"issue":"4","key":"e_1_2_6_7_1","first-page":"341","article-title":"Comparative trial of dapsone vs. TMP\u2010SMZ for primary prophylaxis of Pneumocystis pneumonia","volume":"5","author":"Blum RN","year":"1992","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1580"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01079.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12457","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T15:14:54Z","timestamp":1695482094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/tid.12457"],"URL":"https:\/\/doi.org\/10.1111\/tid.12457","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]}}}